Abstract
This study evaluated and compares the antioxidant activity of six resveratrol analogues. The analogues 4’- Hydroxyphenyl-benzo[d]thiazole (A), p-(N,N-dimethyl)aminobenzylidene-2-aminothiophenol (B) and p-Nitrobenzylidene- 2-aminothiophenol (C) were synthesized and the antioxidant activity was evaluated using the DPPH method. A descriptive statistical analysis and ANOVA followed by the Tukey test, with the aid of software. The best antioxidant activity was demonstrated by compound C (half maximal inhibitory concentration (IC50) = 18.45µM), this compound is two times more active than resveratrol (IC50= 37.28µM). Taken together, the data presented herein suggest that these molecules might serve as potential antioxidant considering that molecular modification is an effective strategy. As such, the compounds described herein can serve as prototypes for further research and the development of novel antioxidant agents.
Keywords: Antioxidants, Chemical synthesis, Resveratrol, Statistical analysis, Structure-activity relationship, Thio-Schiff bases.
Letters in Drug Design & Discovery
Title:Antioxidant Activity of Thio-Schiff Bases
Volume: 10 Issue: 7
Author(s): Juliana Alves dos Santos, Rebeca Mol Lima, Thamiris Vilela Pereira, Antonio Marcio Resende do Carmo, Nadia Rezende Barbosa Raposo and Adilson David da Silva
Affiliation:
Keywords: Antioxidants, Chemical synthesis, Resveratrol, Statistical analysis, Structure-activity relationship, Thio-Schiff bases.
Abstract: This study evaluated and compares the antioxidant activity of six resveratrol analogues. The analogues 4’- Hydroxyphenyl-benzo[d]thiazole (A), p-(N,N-dimethyl)aminobenzylidene-2-aminothiophenol (B) and p-Nitrobenzylidene- 2-aminothiophenol (C) were synthesized and the antioxidant activity was evaluated using the DPPH method. A descriptive statistical analysis and ANOVA followed by the Tukey test, with the aid of software. The best antioxidant activity was demonstrated by compound C (half maximal inhibitory concentration (IC50) = 18.45µM), this compound is two times more active than resveratrol (IC50= 37.28µM). Taken together, the data presented herein suggest that these molecules might serve as potential antioxidant considering that molecular modification is an effective strategy. As such, the compounds described herein can serve as prototypes for further research and the development of novel antioxidant agents.
Export Options
About this article
Cite this article as:
Santos Alves dos Juliana, Lima Mol Rebeca, Pereira Vilela Thamiris, Carmo Marcio Resende do Antonio, Raposo Rezende Barbosa Nadia and Silva David da Adilson, Antioxidant Activity of Thio-Schiff Bases, Letters in Drug Design & Discovery 2013; 10 (7) . https://dx.doi.org/10.2174/1570180811310070002
DOI https://dx.doi.org/10.2174/1570180811310070002 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
UCP2 and CFH Gene Variants with Genetic Susceptibility to Schizophrenia in Turkish Population
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Angiomodulatory and Neurological Effects of Ginsenosides
Current Medicinal Chemistry PTI-609: A Novel Analgesic that Binds Filamin A to Control Opioid Signaling
Recent Patents on CNS Drug Discovery (Discontinued) Flavonoids Protect Cerebrovascular Endothelial Cells through Nrf2 and PI3K from β-Amyloid Peptide-Induced Oxidative Damage
Current Neurovascular Research Schizophrenia and Filicide
Current Women`s Health Reviews Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?
Current Alzheimer Research Tramadol Induced QTc-Interval Prolongation: Prevalence, Clinical Factors and Correlation to Plasma Concentrations
Current Drug Safety Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Emerging Targets in Neurodegeneration: New Opportunities for Alzheimer's Disease Treatment?
Current Topics in Medicinal Chemistry Construction and Analysis of mRNA and lncRNA Regulatory Networks Reveal the Key Genes Associated with Prostate Cancer Related Fatigue During Localized Radiation Therapy
Current Bioinformatics Persian Herbal Medicine in Functional Dyspepsia: A Systematic Review
Current Drug Discovery Technologies Hydrogen Sulfide: From Physiology to Pharmacology
Inflammation & Allergy - Drug Targets (Discontinued) Zebrafish: A Complete Animal Model for In Vivo Drug Discovery and Development
Current Drug Metabolism D-Serine Regulation: A Possible Therapeutic Approach for Central Nervous Diseases and Chronic Pain
Mini-Reviews in Medicinal Chemistry Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
CNS & Neurological Disorders - Drug Targets The Challenges of Chemical Stability Testing of Herbal Extracts in Finished Products Using State-of-the-Art Analytical Methodologies
Current Pharmaceutical Analysis Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets Pharmacogenetics in Type 2 Diabetes: Polymorphisms in Candidate Genes Affecting Responses to Antidiabetic Oral Treatment
Current Pharmacogenomics Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry